FDA To Review Astellas' Fezolinetant New Drug Application, Decision Expected In Feb.

Japanese drug maker Astellas Pharma Inc. (ALPMY,ALPMY) said on Thursday that its New Drug Application for Fezolinetant has been accepted for review by the FDA.

Fezolinetant is an investigational oral, non-hormonal, selective neurokinin 3 receptor antagonist proposed for the treatment of moderate to severe vasomotor symptoms associated with menopause.

The FDA is expected to announce its decision on Fezolinetant on February 22, 2023, following use of a priority review voucher (PRV).

Astellas has recorded 13.1 billion yen of amortization of the intangible asset related to PRV as R&D expense for the first quarter.

For the year to March 31, 2023, the company said that the impact of the drug regulator's clearance is expected to be limited.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT